The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Epigenetic Drug Discovery: Targeting DNA Methyltransferases
Open accessAbstract
Epigenetic modification of DNA leads to changes in gene expression. DNA methyltransferases (DNMTs) comprise a family of nuclear enzymes that catalyze the methylation of CpG dinucleotides, resulting in an epigenetic methylome distinguished between normal cells and those in disease states such as cancer. Disrupting gene expression patterns through promoter methylation has been implicated in many malignancies and supports DNMTs as attractive therapeutic targets. This review focuses on the rationale of targeting DNMTs in cancer, the historical approach to DNMT inhibition, and current marketed hypomethylating therapeutics azacytidine and decitabine. In addition, we address novel DNMT inhibitory agents emerging in development, including CP-4200 and SGI-110, analogs of azacytidine and decitabine, respectively; the oligonucleotides MG98 and miR29a; and a number of reversible inhibitors, some of which appear to be selective against particular DNMT isoforms. Finally, we discuss future opportunities and challenges for next-generation therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143 · cited 6×
“MG98, a 20-bp antisense oligonucleotide, was developed to prevent the translation of DNMT1.”
BackgroundInfluentialTargeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“Unmethylated promoters with intact nucleosomes were repressed despite DNA hypomethylation, possibly due to Polycomb repressor complexes that silence gene transcription through changes in specific histone marks known collectively as PRC reprogramming.(14,170,172) Inhibitors of DNMT1, DNMT3, or both may lead to promoter…”
BackgroundBird, A. (2007) · Nature · doi:10.1038/nature05913 · Cited by 3,011
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 1×
“0 months with conventional care regimens.(125) AZA has been granted marketing authorization by the European Commission for patients with high-risk MDS and AML.”
BackgroundDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 5×
“Among these is 5,6-dihydroazacytidine (5,6-dihydro-AZA), which has demonstrated DNA hypomethylation activity in cells, albeit with 10-fold less potency than AZA.(113) The low cell-based activity of 5,6-dihydro-AZA can be attributed to its inefficient conversion to the activated deoxyribonucleoside triphosphate, leadin…”
BackgroundInfluentialInduction of tumors in mice by genomic hypomethylation
Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083558 · Cited by 1,499
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
Epigenetics and gene expression
Gibney, E. R., & Nolan, C. M. (2010) · Heredity · doi:10.1038/hdy.2010.54 · Cited by 1,109
Cited by
The timeline of epigenetic drug discovery: from reality to dreams
Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 341
The emerging role of epigenetics in human autoimmune disorders
Mazzone, R., Zwergel, C., Artico, M., Taurone, S., Ralli, M., Greco, A., & Mai, A. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0632-2 · Cited by 318
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, X., Zhao, H., Wang, R., Chen, Y., Ouyang, X., Li, W., Sun, Y., & Peng, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01803-z · Cited by 287
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
Metadata
- Authors
- Foulks, J. M., Parnell, K. M., Nix, R. N., Chau, S., Swierczek, K., Saunders, M., Wright, K., Hendrickson, T. F., Ho, K.-K., McCullar, M. V., & Kanner, S. B.
- Venue
- SLAS Discovery
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 17
- Issue
- 1
- Pages
- 2-17
- ISSN
- 2472-5552 (ISSN-L)
- OpenAlex
- W2133117955
- Cited by
- 158
- References
- 11
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic Drug Discovery: Targeting DNA Methyltransferases. https://app.cochat.ai/papers/10.1177/1087057111421212
- The paper
- Foulks, J. M., Parnell, K. M., Nix, R. N., Chau, S., Swierczek, K., Saunders, M., Wright, K., Hendrickson, T. F., Ho, K.-K., McCullar, M. V., & Kanner, S. B. (2012). Epigenetic Drug Discovery: Targeting DNA Methyltransferases. SLAS Discovery. https://doi.org/10.1177/1087057111421212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.